184 related articles for article (PubMed ID: 19147089)
1. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Tefferi A; Levine RL; Kantarjian H
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
[TBL] [Abstract][Full Text] [Related]
2. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A
J Cell Mol Med; 2009 Feb; 13(2):215-37. PubMed ID: 19175693
[TBL] [Abstract][Full Text] [Related]
3. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
4. Oncogenes in myeloproliferative disorders.
Tefferi A; Gilliland DG
Cell Cycle; 2007 Mar; 6(5):550-66. PubMed ID: 17351342
[TBL] [Abstract][Full Text] [Related]
5. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
7. Application of tyrosine kinase inhibitors as a promising targeting treatment for myeloproliferative neoplasms --- review.
Wei M; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1064-70. PubMed ID: 21867645
[TBL] [Abstract][Full Text] [Related]
8. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
9. Advances in understanding and management of myeloproliferative neoplasms.
Vannucchi AM; Guglielmelli P; Tefferi A
CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
Tefferi A; Vardiman JW
Curr Opin Hematol; 2007 Mar; 14(2):115-22. PubMed ID: 17255788
[TBL] [Abstract][Full Text] [Related]
11. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.
Wadleigh M; Tefferi A
Int J Hematol; 2010 Mar; 91(2):174-9. PubMed ID: 20191332
[TBL] [Abstract][Full Text] [Related]
12. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
[TBL] [Abstract][Full Text] [Related]
13. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.
Tefferi A; Gilliland G
Best Pract Res Clin Haematol; 2006; 19(3):365-85. PubMed ID: 16781478
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations.
Caramazza D; Hussein K; Siragusa S; Pardanani A; Knudson RA; Ketterling RP; Tefferi A
Eur J Haematol; 2010 Mar; 84(3):191-200. PubMed ID: 20002154
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic mechanisms in myeloproliferative disorders.
Delhommeau F; Pisani DF; James C; Casadevall N; Constantinescu S; Vainchenker W
Cell Mol Life Sci; 2006 Dec; 63(24):2939-53. PubMed ID: 17131059
[TBL] [Abstract][Full Text] [Related]
16. Molecular diagnosis of myeloproliferative neoplasms.
Patnaik MM; Tefferi A
Expert Rev Mol Diagn; 2009 Jul; 9(5):481-92. PubMed ID: 19580432
[TBL] [Abstract][Full Text] [Related]
17. Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis.
Tefferi A; Sirhan S; Sun Y; Lasho T; Finke CM; Weisberger J; Bale S; Compton J; LeDuc CA; Pardanani A; Thorland EC; Shevchenko Y; Grodman M; Chung WK
Leuk Res; 2009 May; 33(5):662-4. PubMed ID: 18937974
[TBL] [Abstract][Full Text] [Related]
18. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
Levine RL; Pardanani A; Tefferi A; Gilliland DG
Nat Rev Cancer; 2007 Sep; 7(9):673-83. PubMed ID: 17721432
[TBL] [Abstract][Full Text] [Related]
19. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
Tefferi A; Vardiman JW
Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
Kiladjian JJ; Chomienne C; Fenaux P
Leukemia; 2008 Nov; 22(11):1990-8. PubMed ID: 18843285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]